Kjartan Herrik
banner
herrix.bsky.social
Kjartan Herrik
@herrix.bsky.social
Danish Neuroscientist working on developing new treatments to patients with neurological or neuropsychiatric conditions
Pinned
We just published the interesting story of the making of an #NMDAR targeting compound that showed promising effects in preclinical models predicting anti-depressant effects. To get the compound into the brain we used a prodrug strategy.
Advancements in NMDA Receptor-Targeted Antidepressants: From d-Cycloserine Discovery to Preclinical Efficacy of Lu AF90103
The discovery of d-cycloserine (DCS), a partial agonist of the NMDA receptor that exhibits antidepressant effects without the psychotomimetic effects of ketamine, has fueled interest in new NMDA-targe...
pubs.acs.org
www.linkedin.com/posts/kjarta...

Så ligger der Drughunters 2026 opgaver klar til vakse gymnasieelever, der vil prøve kræfter med at udvikle nye og bedre lægemidler til sygdomme i centralnervesystemet. Der er opgaver i biologi, biotek, kemi og matematik.
Opgaver | Kjartan Herrik
Så ligger der Drughunters 2026 opgaver klar til vakse gymnasieelever, der vil prøve kræfter med at udvikle nye og bedre lægemidler til sygdomme i centralnervesystemet. Der er opgaver i biologi, biotek...
www.linkedin.com
November 3, 2025 at 12:43 PM
Always a pleasure to welcome young students participating in the Drughunters and Brain Battle competitions. Full of knowledge and great new ideas.
#opuspanelet #drughunters #brainbattle | Kjartan Herrik
What a day! Drughunters and Brain Battle finalists outperformed this year! The highschool and master students that participated this year were super sharp and inspired eachother as well as me and my...
www.linkedin.com
May 4, 2025 at 1:41 PM
Thanks to #albergstrom for making this cover art for the Ascic et al paper. It portrays a person lost in dark thoughts. The prodrug strategy enables crossing the blood–brain barrier for a compound targeting the glycine site of the NMDA receptor (blue). Read the paper to learn more ...
January 28, 2025 at 9:20 PM
We just published the interesting story of the making of an #NMDAR targeting compound that showed promising effects in preclinical models predicting anti-depressant effects. To get the compound into the brain we used a prodrug strategy.
Advancements in NMDA Receptor-Targeted Antidepressants: From d-Cycloserine Discovery to Preclinical Efficacy of Lu AF90103
The discovery of d-cycloserine (DCS), a partial agonist of the NMDA receptor that exhibits antidepressant effects without the psychotomimetic effects of ketamine, has fueled interest in new NMDA-targe...
pubs.acs.org
November 22, 2024 at 12:44 PM